Ignacio
Gil Bazo
Researcher to 2022
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublications in collaboration with researchers from David Geffen School of Medicine at UCLA (1)
2019
-
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 20, Núm. 12, pp. 1655-1669